told you guys , ceo does not get a #$%$ about the shareholders and updating them. He needs to be FIRED ASAP
email the lady at arrys ir department and remind her what her job is , to promote and update the shareholders.
OK if you are right I will make a public apology to squarer, with his track record I don't think this will be happening anytime soon. I will also invite him and put him and his family up at a nice resort in Newport Beach (5 star) I don't think that will be happening anytime soon. Stock has to hit 30.00 next year in order to full this order
but I'm sure that doesn't cross your mind as you collect your huge paychecks
SHUT your piehole burka (RON) , RON himself spewing more smoke and mirrors, as a matter of fact I know you(RON) posted this.
agreed100000% he smokes good pipe !! He will go down in the history books as the best BSer ever, maybe he cam issue more shares............ the guy is horrific at management
This is why AstraZeneca will buy ARRY to expand its pipeline:
AstraZeneca's keenly awaited cancer immunotherapy drug durvalumab may not get to market as quickly as first hoped but the company said on Thursday it was more confident than ever in its oncology development pipeline
ONTY and LOXO updates will make ARRY pop , keep an eye on ONTY tomorrow AH and LOXO next week. Still need to get fire the ceo
Kind of reminds me of Dendreon (DNDN) CEO, I think he had to flee the country .
with some real results, let me see more compensation for the directors , more options, no real insider buy, same #$%$ about partner, by 12-31-15 hell be saying we will announce a partner 2016. THE STREET is tired of the smoke and mirrors...............maybe hell get some pressure from the institutions he sucked in
A REAL CEO who believes in his own company: look at the investment amount !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Biogen Inc. (NASDAQ: BIIB) had a huge purchase hit the tape this past week, one that may very well turn some heads in the biotech world. A director at the company bought a stunning 310,000 shares of the biotech giant at prices between $276.77 and $277.70 per share. The total for the purchase was an incredible $86 million. The stock is down almost $200 per share since highs that were posted last March. Shares were changing hands at $290.51 as trading on Friday concluded, so it appears to be a well-timed buy